Precise Bio

Winston-salem, United States Founded: 2015 • Age: 11 yrs
Developer of integrated 3D printing and tissue-engineering platform
Request Access

About Precise Bio

Precise Bio is a company based in Winston-salem (United States) founded in 2015 by Shay Soker, Aryeh Batt, and Anthony Atala.. Precise Bio has raised $12 million across 3 funding rounds from investors including ZEISS. The company has 6 employees as of December 31, 2022. Precise Bio offers products and services including Precise Bio Platform and Ophthalmology Unit. Precise Bio operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Collplant, Triastek and ROKIT Healthcare, among others.

  • Headquarter Winston-salem, United States
  • Employees 6 as on 31 Dec, 2022
  • Founders Shay Soker, Aryeh Batt, Anthony Atala
  • Sectors
    Healthcare
    Technology
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Precise Bio, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Technology → Robotics, Automation & Advanced Manufacturing
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $12 M (USD)

    in 3 rounds

  • Latest Funding Round
    $12 M (USD), Series B

    Jan 17, 2024

  • Investors
  • Employee Count
    6

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Precise Bio

Precise Bio offers a comprehensive portfolio of products and services, including Precise Bio Platform and Ophthalmology Unit. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Integrated system for bio-fabricating tissues and organs using patient cells.

Dedicated unit for eye-related bio-fabrication and tissue engineering.

People of Precise Bio
Headcount 10-50
Employee Profiles 12
Board Members and Advisors 1
Employee Profiles
People
Lior Rosenberg Belmaker
Head Of CMC
People
Amos Eitan
VP, R&D
People
Yishay Hayardeni
VP. Projects & System
People
Shay Soker
Co-Founder & CSO

Unlock access to complete

Board Members and Advisors
people
Richard L. Lindstrom
Advisor

Unlock access to complete

Funding Insights of Precise Bio

Precise Bio has successfully raised a total of $12M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $12.0M
  • First Round

    (08 Feb 2022)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2024 Amount Series B - Precise Bio Valuation

investors

Jul, 2022 Amount Seed - Precise Bio Valuation ZEISS
Feb, 2022 Amount Debt – Conventional - Precise Bio Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Precise Bio

Precise Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include ZEISS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Provider of diversified optics for microscopic instruments, medical imaging systems and more
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Precise Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Precise Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Precise Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Precise Bio

Precise Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Collplant, Triastek and ROKIT Healthcare, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Desktop bioprinter for genes and proteins production is developed.
domain founded_year HQ Location
3D bioprinters and bioinks are developed for research applications.
domain founded_year HQ Location
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
domain founded_year HQ Location
Provider of 3D printing pharmaceutical technology platform for drug design
domain founded_year HQ Location
4D bio-printer solutions for tissue regeneration are provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Precise Bio

When was Precise Bio founded?

Precise Bio was founded in 2015 and raised its 1st funding round 7 years after it was founded.

Where is Precise Bio located?

Precise Bio is headquartered in Winston-salem, United States. It is registered at Winston-salem, North Carolina, United States.

Who is the current CEO of Precise Bio?

Aryeh Batt is the current CEO of Precise Bio. They have also founded this company.

Is Precise Bio a funded company?

Precise Bio is a funded company, having raised a total of $12M across 3 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $15.53M, raised on Feb 08, 2022.

How many employees does Precise Bio have?

As of Dec 31, 2022, the latest employee count at Precise Bio is 6.

What does Precise Bio do?

Precise Bio was founded in 2015 in Winston-Salem, United States. An integrated 3D printing and tissue-engineering platform is developed for the regenerative medicine sector. Repeatable bio-fabricated organs are produced from patients own cells, targeting cardiology, orthopedics, dermatology, and additional areas. The lead product, a 3D cardiac tissue patch, is implanted post-myocardial infarction to restore cardiac muscle viability and functionality.

Who are the top competitors of Precise Bio?

Precise Bio's top competitors include Nuclera Nucleics, Allevi and Collplant.

What products or services does Precise Bio offer?

Precise Bio offers Precise Bio Platform and Ophthalmology Unit.

Who are Precise Bio's investors?

Precise Bio has 1 investor. Key investors include ZEISS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available